Adiposity and Response to ADT ± AR Pathway Inhibitors (ARPI) in Men with Metastatic Hormone-Sensitive Prostate Cancer (Mhspc).

Adiposity and Response to ADT ± AR Pathway Inhibitors (ARPI) in Men with Metastatic Hormone-Sensitive Prostate Cancer (Mhspc). | AMiner